Towards the reconstitution and a structure of the Plasmodium vacuolar translocon

疟原虫液泡易位子的重建和结构

• 批准号: 9167109
• 负责人: Pascal Francois Egea
• 金额: $ 22.25万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-06-24 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9167109
• 关键词: ATP phosphohydrolase; Adverse effects; Amino Acid Sequence; Antimalarials; Apicomplexa; Asparagine; Automobile Driving; Bacteria; Biological Process; Blood; Catalytic Domain; Cells; Cessation of life; Chemicals; Clinical; Codon Nucleotides; Complex; Cryoelectron Microscopy; Cryptosporidium; Cytoplasm; Cytosol; Disease; Drug Design; Drug Targeting; Drug resistance; Erythrocytes; Eukaryota; Face; Fever; Gap Junctions; Genome; Goals; Human; Hybrids; Infection; Insect Control; Insecta; Invaded; Length; Licensing; Life Cycle Stages; Life Style; Malaria; Mediating; Membrane; Methods; Molecular Chaperones; Molecular Machines; Mosquito-borne infectious disease; Multi-Drug Resistance; N-terminal; Organism; Orthologous Gene; Parasites; Pathogenesis; Peptide Sequence Determination; Pharmaceutical Preparations; Pharmacotherapy; Plasmodium; Plasmodium falciparum; Prevention; Process; Property; Protein Export Pathway; Protein Subunits; Proteins; Proteome; Recombinants; Research; Rest; Source; Staging; Stream; Stretching; Structure; Synthetic Genes; System; Toxoplasma; Triplet Multiple Birth; Vacuole; Virulence; X-Ray Crystallography; Yeasts; base; design; disorder control; heat-shock proteins 110; improved; inhibitor/antagonist; knock-down; macromolecule; microorganism; novel; prevent; protein complex; protein transport; reconstitution; targeted treatment; three dimensional structure

Plasmodium falciparum, the causative agent of malaria, is responsible for 600,000 deaths every year and causes clinical illness in 300-500 million more. Although several drugs are currently used to treat malaria, the emergence and spread of drug-resistant parasites is a major threat to effective disease control. Novel antimalarial therapies targeting essential and original parasitic processes are urgently needed. Central to the capacity of this microorganism to grow inside red blood cells and to thrive inside the blood stream is its ability to export about 5-8% of its proteins beyond an encasing vacuole and into the cytosol of its host cell. The intracellular survival of Plasmodium falciparum within human red blood cells is dependent on export of parasite proteins that remodel the infected host cell to support its virulence and parasitic lifestyle. To do so, the parasite installs a large protein complex, the Plasmodium Translocon of EXported proteins) (PTEX), in the membrane of the encasing vacuole that enables it to export these hundreds of proteins into the red blood cell. PTEX is composed of five parasite proteins: the EXported Protein 2 (EXP2) that assembles into a trans-membrane pore to conduct the cargo proteins, the ATPase HSP101 that provides the energy driving the export process by unfolding the cargo proteins and threading them through the EXP2 channel and, proteins PTEX150, PTEX88 and TRX2 that recognize, prepare and deliver the translocated proteins to the `channel-engine' complex. The essential subunits EXP2, HSP101 and PTEX150 tightly associate into a core complex. As a common portal for numerous crucial biological processes, PTEX represents an Achilles heel in Plasmodium's life cycle. However, to this day, the structure and detailed mechanism of action of this complex protein export machine remain unknown. To this aim, we have already purified subunits TRX2, EXP2, and HSP101 expressed from recombinant sources and solved the crystal structures of the TRX2 subunit and the N-terminal domain of the HSP101 ATPase. Through the combination of cryo-electron microscopy and X-ray crystallography, we will pursue the structure of the ATPase HSP101, a key regulator of protein trafficking in Plasmodium. We also seek to complete the reconstitution of PTEX150. As a consequence of the high AT codon bias of Plasmodium's genome, PTEX150 contains several asparagine-rich repeats, sequences with a high propensity for disorder and aggregation. To overcome this obstacle, we propose to explore the use of the Plasmodium HSP110, a chaperone shown to stabilize the asparagine-rich parasitic proteins, as a coexpression partner to enable and/or improve expression of PTEX150 and its reconstitution into a functional PTEX ternary core. Using yeast or insect cells as heterologous expression systems, we will use synthetic genes to coexpress PTEX subunits in presence of this specialized chaperone and reconstitute higher order PTEX complexes.

恶性疟原虫是疟疾的病原体，每年造成60万人死亡，并导致3亿至5亿人临床患病。虽然目前有几种药物用于治疗疟疾，但抗药性寄生虫的出现和传播是有效控制疾病的主要威胁。迫切需要针对基本和原始寄生虫过程的新型抗疟疗法。这种微生物在红细胞内生长并在血流中茁壮成长的能力的核心是其将约5-8%的蛋白质输出到包围的空泡之外并进入其宿主细胞的胞质溶胶中的能力。恶性疟原虫在人红细胞内的细胞内存活依赖于寄生虫蛋白的输出，这些寄生虫蛋白重塑受感染的宿主细胞以支持其毒力和寄生生活方式。为了做到这一点，寄生虫将一个大的蛋白质复合物，即输出蛋白质的疟原虫易位（PTEX），安装在包裹液泡的膜上，使其能够将这数百种蛋白质输出到红细胞中。PTEX由五种寄生虫蛋白组成：组装成跨膜孔以传导货物蛋白的输出蛋白2（EXP 2），ATP酶HSP 101，其通过解折叠货物蛋白并使它们穿过EXP 2通道来提供驱动输出过程的能量，以及识别制备并将易位的蛋白质递送至“通道-引擎”复合物。必需亚基EXP 2、HSP 101和PTEX 150紧密结合成核心复合物。作为许多关键生物过程的共同门户，PTEX代表了疟原虫生命周期中的阿喀琉斯之踵。然而，直到今天，这种复杂的蛋白质输出机器的结构和详细的作用机制仍然未知。为此，我们已经纯化了重组来源表达的TRX 2、EXP 2和HSP 101亚基，并解析了TRX 2亚基和HSP 101 ATP酶N端结构域的晶体结构。通过冷冻电子显微镜和X射线晶体学的结合，我们将追求的ATP酶HSP 101，在疟原虫蛋白质运输的关键调节器的结构。我们还寻求完成PTEX 150的重建。作为疟原虫基因组的高AT密码子偏好的结果，PTEX 150含有几个富含天冬酰胺的重复序列，这些序列具有高度的无序和聚集倾向。为了克服这一障碍，我们建议探索使用疟原虫HSP 110， 显示稳定富含天冬酰胺的寄生蛋白的分子伴侣，作为共表达伴侣，以实现和/或改善PTEX 150的表达及其重建成功能性PTEX三元核心。使用酵母或昆虫细胞作为异源表达系统，我们将使用合成基因在这种专门的分子伴侣存在下共表达PTEX亚基，并重建高阶PTEX复合物。